MoneyWorks4Me

Aurobindo Pharma informs about Press Release

27 Jul 2015 Evaluate

Aurobindo Pharma has informed about a Press Release dated July 27, 2015 titled ‘Aurobindo Pharma receives USFDA Approval for Esmolol Hydrochloride Injection’.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma Share Price

1631.65 0.65 (0.04%)
28-Aug-2026 13:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1923.25
Dr. Reddys Labs. 1180.50
Cipla 1415.90
Lupin 2171.05
Zydus Lifesciences 1174.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: